Several brokerages have updated their recommendations and price targets on shares of Gilead Sciences (NASDAQ: GILD) in the last few weeks:

• 10/31/2022 – Gilead Sciences was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
• 10/31/2022 – Gilead Sciences was upgraded by analysts at Barclays PLC from an "underweight" rating to an "equal weight" rating. They now have a $76.00 price target on the stock, up previously from $60.00.
• 10/31/2022 – Gilead Sciences had its price target raised by analysts at Maxim Group from $84.00 to $92.00. They now have a "buy" rating on the stock.
• 10/28/2022 – Gilead Sciences had its price target raised by analysts at JPMorgan Chase & Co. from $80.00 to $87.00. They now have an "overweight" rating on the stock.
• 10/28/2022 – Gilead Sciences was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $96.00 price target on the stock, up previously from $79.00.
• 10/28/2022 – Gilead Sciences had its price target raised by analysts at Royal Bank of Canada from $79.00 to $82.00. They now have an "outperform" rating on the stock.
• 10/28/2022 – Gilead Sciences had its price target raised by analysts at Cowen Inc. from $75.00 to $80.00. They now have an "outperform" rating on the stock.
• 10/28/2022 – Gilead Sciences had its price target raised by analysts at BMO Capital Markets from $63.00 to $72.00. They now have a "market perform" rating on the stock.
• 10/28/2022 – Gilead Sciences had its price target raised by analysts at Morgan Stanley from $67.00 to $68.00. They now have an "equal weight" rating on the stock.
• 10/28/2022 – Gilead Sciences had its price target raised by analysts at Wells Fargo & Company from $74.00 to $75.00. They now have an "equal weight" rating on the stock.
• 10/28/2022 – Gilead Sciences had its price target raised by analysts at Jefferies Financial Group Inc. from $78.00 to $86.00. They now have a "buy" rating on the stock.
• 10/28/2022 – Gilead Sciences was upgraded by analysts at Truist Financial Co. from a "hold" rating to a "buy" rating. They now have a $91.00 price target on the stock, up previously from $76.00.
• 10/28/2022 – Gilead Sciences had its price target raised by analysts at Cowen Inc from $75.00 to $80.00.
• 10/13/2022 – Gilead Sciences had its price target raised by analysts at Morgan Stanley from $65.00 to $67.00. They now have an "equal weight" rating on the stock.
• 10/12/2022 – Gilead Sciences had its price target raised by analysts at Barclays PLC from $56.00 to $60.00. They now have an "underweight" rating on the stock.
• 10/12/2022 – Gilead Sciences is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
• 10/4/2022 – Gilead Sciences was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating. They now have a $80.00 price target on the stock, up previously from $72.00.
• 9/15/2022 – Gilead Sciences had its "market perform" rating reaffirmed by analysts at SVB Leerink LLC.
• 9/15/2022 – Gilead Sciences had its price target raised by analysts at Truist Financial Co. from $71.00 to $76.00. They now have a "hold" rating on the stock.
• 9/13/2022 – Gilead Sciences had its price target raised by analysts at Wells Fargo & Company from $63.00 to $74.00. They now have an "equal weight" rating on the stock.
• 9/12/2022 – Gilead Sciences had its price target raised by analysts at Piper Sandler from $74.00 to $79.00.

Gilead Sciences Trading Down 1.0 %

Shares of GILD opened at $78.46 on Tuesday. The stock has a fifty day moving average price of $65.54 and a two-hundred day moving average price of $63.35. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.27 and a current ratio of 1.43. Gilead Sciences, Inc. has a 52-week low of $57.17 and a 52-week high of $79.61. The company has a market cap of $98.34 billion, a price-to-earnings ratio of 29.61, a PEG ratio of 0.77 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD – Get Rating) last released its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.51 by $0.07. The company had revenue of $6.26 billion during the quarter, compared to analysts' expectations of $5.88 billion. Gilead Sciences had a return on equity of 38.82% and a net margin of 12.29%. Analysts predict that Gilead Sciences, Inc. will post 6.84 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

Institutional Investors Weigh In On Gilead Sciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. Landmark Wealth Management LLC acquired a new stake in shares of Gilead Sciences in the 1st quarter valued at $30,000. JFS Wealth Advisors LLC grew its stake in shares of Gilead Sciences by 68.1% during the third quarter. JFS Wealth Advisors LLC now owns 400 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 162 shares during the period. Pacifica Partners Inc. grew its stake in shares of Gilead Sciences by 179.7% during the third quarter. Pacifica Partners Inc. now owns 414 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 266 shares during the period. TFO TDC LLC acquired a new stake in shares of Gilead Sciences during the first quarter worth $27,000. Finally, Horan Securities Inc. grew its stake in shares of Gilead Sciences by 217.9% during the third quarter. Horan Securities Inc. now owns 461 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 316 shares during the period. 78.58% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Featured Stories

• Get a free copy of the StockNews.com research report on Gilead Sciences (GILD)
• Here's Why Harley-Davidson is Roaring Higher
• As Mega Caps Get Crushed, This Mid Cap Tech Stock Is Crushing It
• Saia Stock Is Ready To Switch Gears And Move Higher
• Why Investors Are Suddenly Excited About Vaxcyte
• Is The Meta Platforms Stock Meltdown a Rare Buying Opportunity?

Receive News & Ratings for Gilead Sciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.